What is Wedbush's Forecast for Kura Oncology Q1 Earnings?

Kura Oncology, Inc. (NASDAQ:KURA - Free Report) - Research analysts at Wedbush dropped their Q1 2025 earnings per share (EPS) estimates for Kura Oncology in a report issued on Thursday, February 27th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings per share of ($0.87) for the quarter, down from their previous forecast of ($0.70). Wedbush currently has a "Outperform" rating and a $36.00 target price on the stock. The consensus estimate for Kura Oncology's current full-year earnings is ($2.44) per share. Wedbush also issued estimates for Kura Oncology's Q2 2025 earnings at ($0.95) EPS, Q3 2025 earnings at $1.36 EPS, Q4 2025 earnings at ($1.05) EPS, FY2025 earnings at ($1.51) EPS, FY2026 earnings at ($1.71) EPS, FY2027 earnings at ($4.08) EPS and FY2028 earnings at ($1.33) EPS.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.43. The firm had revenue of $53.88 million for the quarter, compared to analysts' expectations of $57.96 million.

Other research analysts have also issued reports about the company. StockNews.com upgraded Kura Oncology from a "sell" rating to a "hold" rating in a report on Thursday, February 27th. Bank of America decreased their target price on Kura Oncology from $36.00 to $29.00 and set a "buy" rating for the company in a report on Friday, November 22nd. Scotiabank decreased their target price on Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating for the company in a report on Wednesday, January 8th. Jefferies Financial Group decreased their target price on Kura Oncology from $32.00 to $28.00 and set a "buy" rating for the company in a report on Thursday, November 21st. Finally, BTIG Research lowered Kura Oncology from a "buy" rating to a "neutral" rating in a report on Thursday, February 6th. Four research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $25.50.

Remove Ads

Kura Oncology Trading Up 4.5 %

Shares of KURA traded up $0.33 during midday trading on Monday, hitting $7.70. 1,438,284 shares of the stock were exchanged, compared to its average volume of 1,598,446. Kura Oncology has a 52-week low of $6.98 and a 52-week high of $24.17. The stock has a fifty day simple moving average of $8.04 and a 200 day simple moving average of $13.51. The firm has a market cap of $598.78 million, a P/E ratio of -3.26 and a beta of 0.85. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47.

Institutional Trading of Kura Oncology

A number of hedge funds and other institutional investors have recently made changes to their positions in KURA. RA Capital Management L.P. acquired a new stake in shares of Kura Oncology during the fourth quarter worth about $38,769,000. Millennium Management LLC increased its position in shares of Kura Oncology by 180.1% during the fourth quarter. Millennium Management LLC now owns 2,367,148 shares of the company's stock worth $20,618,000 after purchasing an additional 1,521,954 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Kura Oncology during the fourth quarter worth about $8,518,000. Marshall Wace LLP acquired a new stake in shares of Kura Oncology during the fourth quarter worth about $8,265,000. Finally, D. E. Shaw & Co. Inc. increased its position in shares of Kura Oncology by 172.0% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,151,195 shares of the company's stock worth $10,027,000 after purchasing an additional 727,987 shares in the last quarter.

Insiders Place Their Bets

In other Kura Oncology news, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the sale, the insider now directly owns 88,253 shares of the company's stock, valued at $694,551.11. The trade was a 5.32 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the sale, the senior vice president now owns 88,193 shares in the company, valued at $694,078.91. This trade represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,729 shares of company stock valued at $92,307 in the last ninety days. Insiders own 5.50% of the company's stock.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.